10B. [***] Antibodies The Parties acknowledge that the use of any [***] Antibodies in a Collaboration Product or Unilateral Product shall be subject to the terms and conditions of the [***] Agreement. [***] is an [***] (as that term is defined in the [***] Agreement). Genmab hereby grants to Biontech a sublicense under its rights under the [***] Agreement for the [***] Antibodies it being understood that Sections 9.3, 14.7c and 14.7d of this Agreement shall apply mutatis mutandis to this sublicense.
Appears in 2 contracts
Sources: License and Collaboration Agreement (BioNTech SE), License and Collaboration Agreement (BioNTech SE)